Fundraising Fox
Maxcyte
NASDAQ: MXCTUnicorn · $1.3BGaithersburg, US · Delaware corporation · 1 known investors
Find your way into Maxcyte
Sign up to see every warm intro you have to Maxcyte
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Maxcyte team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
MaxCyte develops non-viral electroporation and cell-engineering technology used to transfect and engineer cells for research and therapeutic development. It also offers gene editing risk assessment services and licensing partnerships to help cell and gene therapy developers advance toward clinical and commercial stages.
Founders & leadership
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$2.5M disclosed across 2 rounds · 2014–2016
▶$760.3KraisedSep 2016 · 9 investors · BiotechnologyRule 506(b)
- Madhusudan V PeshwaExecutive Officer
- J Stark ThompsonDirector
- Douglas A DoerflerExecutive Officer, Director
- Arthur M MandellDirector
- John JohnstonDirector
- Stanley C ErckDirector
- Ronald E HoltzExecutive Officer, Director
- Thomas RossExecutive Officer
- William BrookeDirector
- Offering amount
- $760.3K
- Amount sold
- $760.3K
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.7MraisedDec 2014 · 21 investors · BiotechnologyRule 506(b)
- Arthur MandellDirector
- Sinclair DunlopDirector
- Will BrookeDirector
- Madhusudan PeshwaExecutive Officer
- Dennis DoughertyDirector
- J. Stark ThompsonDirector
- Stan ErckDirector
- Douglas A. DoerflerExecutive Officer, Director
- Ronald E. HoltzExecutive Officer
- Karen DonatoExecutive Officer
- Offering amount
- $1.7M
- Amount sold
- $1.7M
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Frequently asked questions
- What does Maxcyte do?
- MaxCyte develops non-viral electroporation and cell-engineering technology used to transfect and engineer cells for research and therapeutic development. It also offers gene editing risk assessment services and licensing partnerships to help cell and gene therapy developers advance toward clinical and commercial stages.
- Who founded Maxcyte?
- Maxcyte was founded by Douglas A. Doerfler.
- Who are Maxcyte's investors?
- Maxcyte's investors include Sofinnova Partners.
- How much funding has Maxcyte raised?
- Maxcyte has disclosed $2.5M raised across 2 rounds.
- Where is Maxcyte headquartered?
- Maxcyte is headquartered in Gaithersburg, US.